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Abstract 
Recurrent, de novo, meiotic non-allelic homologous recombination events between 
low copy repeats, termed LCR22s, leads to the 22q11.2 deletion syndrome 
(22q11.2DS; velo-cardio-facial syndrome/DiGeorge syndrome). Although most 
22q11.2DS patients have a similar sized 3 million base pair (Mb), LCR22A-D 
deletion, some have nested LCR22A-B or LCR22A-C deletions. Our goal is to 
identify additional recurrent 22q11.2 deletions associated with 22q11.2DS, serving 
as recombination hotspots for meiotic chromosomal rearrangements. Here, using 
data from Affymetrix 6.0 microarrays on 1680 22q11.2DS subjects, we identified 
what appeared to be a nested proximal 22q11.2 deletion in 38 (2.3%) of them. Using 
molecular and haplotype analyses from 14 subjects and their parent(s) with available 
DNA, we found essentially three types of scenarios to explain this observation. In 
eight subjects, the proximal breakpoints occurred in a small sized 12 kb LCR distal to 
LCR22A, referred to LCR22Aþ, resulting in LCR22Aþ-B or LCR22Aþ-D deletions. 
Six of these eight subjects had a nested 22q11.2 deletion that occurred during 
meiosis in a parent carrying a benign 0.2 Mb duplication of the LCR22A 
LCR22Aþregion with a breakpoint in LCR22Aþ. Another six had a typical de novo 
LCR22A-D deletion on one allele and inherited the LCR22A-Aþduplication from the 
other parent thus appearing on microarrays to have a nested deletion. 
LCR22Aþmaps to an evolutionary breakpoint between mice and humans and 
appears to serve as a local hotspot for chromosome rearrangements on 22q11.2. 
 
Introduction 
The 22q11.2 deletion syndrome (22q11.2DS), also named DiGeorge syndrome 
(MIM# 188400) and velo-cardio-facial syndrome (VCFS, MIM# 192430), is the most 
common chromosomal microdeletion disorder in humans with an estimated 
incidence of 1 in 4000 live births (1–6). The major clinical characteristics of the 
syndrome include learning disabilities and psychiatric disorders, characteristic facial 
appearance, hypernasal speech due to velo-pharyngeal insufficiency, neonatal 
hypocalcemia, immune deficiency and congenital heart malformations (7–10). 
Approximately 90% of individuals affected with the syndrome have a similarly sized 
de novo, _3 million base pair (Mb) hemizygous deletion on chromosome 22q11.2 
(11,12). The recurrent deletion is caused by meiotic non-allelic homologous 
recombination (NAHR) events, when chromosomes misalign and undergo unequal 
crossing over, between flanking low copy repeats (LCRs; or segmental duplications) 
termed LCR22. There are several large sized LCR22s that map to the 3 Mb region 
on 22q11.2 (13–16), termed, LCR22A, -B, -C and -D (15). The 3 Mb deletion is 
caused by NAHR events between LCR22A and LCR22D and is frequently referred to 
as the LCR22A-D deletion (13). A subset has nested deletions between LCR22A-B 
and LCR22A-C, resulting in smaller 1.5 Mb LCR22A-B or 2 Mb LCR22A-C deletions, 
respectively, although the LCR22A-C deletion is relatively rare (13–15). Each LCR22 
is comprised of subunits or modules forming a complex mosaic pattern of>99% 
sequence identity within modules of different orientations and copy number (16). 
These modules formed during primate evolution and are not present in mice (17). 
Recently, an inversion polymorphism was discovered between LCR22B-D or 
LCR22C-D (18). This inversion is required for the LCR22A-D deletion to take place. 
It is present in the healthy parent in which the de novo deletion occurs (18). The 
presence of an inversion occurs commonly in normal individuals and it reflects the 
complexity of the 22q11.2 region. It also provides new insights into the mechanism 
that leads to the LCR22A-D deletion (18). Besides the four main LCR22s associated 
with the characteristic 22q11.2DS phenotype, there are additional dispersed 
modules of LCRs (segmental duplications) that are smaller, which map within this 3 
Mb interval (19). Genomic architecture is a key mutational mechanism for causing 
human congenital anomaly disorders and also for promoting genetic variation (20). 
The role of these LCRs or other possible sequence elements leading towards 
recurrent rearrangements and resulting in 22q11.2DS, has not been determined. 
Such investigation requires a sufficiently large sized cohort where DNA or genetic 
data are available. In this report, we processed and examined Affymetrix 6.0 array 
data from 1680 unrelated probands with 22q11.2DS to better delineate the 
prevalence of novel recurrent nested 22q11.2 deletions. We chose to investigate 
recurrent deletions as a priority because the region of chromosome breakage might 
shed light on molecular mechanisms responsible for abnormal meiotic chromosome 
rearrangements. With available material from patient-parent trios, we performed 
quantitative PCR, microsatellite marker analysis and FISH mapping studies to define 
a novel deletion type. We also compared the local genomic architecture where 
breakpoints occurred between humans and mice, to better understand the potential 
role in how the 22q11.2 region evolved. 
 
Results 
Nested 22q11.2 deletions The first goal of the current study is to identify novel 
recurrent nested deletions within the LCR22A-D region by generating and analysing 
Affymetrix 6.0 microarray data from 1680, 22q11.2DS subjects. We first identified 
deletion sizes in the cohort and found 1519 (90.4%) had a 3 Mb LCR22A-D deletion, 
88 (5.2%) had an LCR22A-B deletion and 31 (1.9%) had an LCR22A-C deletion 
(Table 1). This is similar to what has been found before with smaller sample sizes. 
The LCR22A-B, A-C and A-D deletions were concordant in 539 samples that were 
also assayed using MLPA (data not shown). We found one new type of recurrent 
22q11.2 deletion from analysis of the microarrays. In 38 (2.3%) subjects, we 
identified possible recurrent nested deletions of 1.3 Mb (n¼2) and 2.8 Mb (n¼36) 
(Table 1) with a similar appearing proximal (centromeric) breakpoint distal to PRODH 
(Proline dehydrogenase 1) and proximal to DGCR2 (DiGeorge critical region gene 
2). The distal breakpoints mapped to LCR22B or LCR22D, respectively. 
Representative log2 ratio plot data are shown in Supplementary Material, Figure S2A 
and illustrated in Supplementary Material, Figure S2B. Upon investigating the 
literature, a few reports described individual subjects with a similar type of nested 
deletion (15,26,29,30). Based upon Affymetrix 6.0 data for all 38 samples (data not 
shown), the proximal breakpoint interval appeared to be in a similar location among 
all subjects. We next wanted to narrow the proximal deletion endpoints to confirm 
this possibility. We had DNA available from 19 of the 38 subjects with nested 
deletions. In addition, we had DNA from three different 22q11.2DS individuals that 
were not subjected to Affymetrix 6.0 analysis but had evidence from microsatellite 
markers that they had the 1.3 or 2.8 Mb nested deletion(s) (27), making a total of 22. 
The nested proximal deletion is in a 12 kb LCR, termed LCR22Aþ To map the 
position of the proximal chromosome breakpoints in the 22 DNA samples, we 
performed qPCR assays with primersspanning the interval found by Affymetrix 6.0 
arrays. Results from a representative trio are shown in Figure 1. In this trio, the 
female proband, KD23, has a de novo 22q11.2 deletion as illustrated in Figure 1A 
(left). A cartoon of the different possible alleles is also shown in Figure 1A (right). 
Primers pairs for qPCR (Supplementary Material, Table S2) to unique sequences in 
the DGCR5-DGCR2 region are shown with respect to LCRs and genes in the UCSC 
Genome Browser snapshot in Figure 1A (hg19 assembly; bottom). We then 
performed qPCR assays on 22 samples with available DNA along with control 
samples that did not have a 22q11.2 deletion or had a typical 3 Mb 22q11.2 deletion 
(Supplementary Material, Fig. S3). Results from qPCR analysis of the KD23 trio is 
shown in Figure 1B. The breakpoints in all 22 subjects mapped between DGCR10–1 
and DGCR2–1 qPCR products (Supplementary Material, Fig. S3). The two qPCR 
products flank a 12 kb LCR that we termed LCR22Aþ(Fig. 1A). We could not further 
narrow the interval within LCR22Aþbecause the distal breakpoints are embedded 
within complex LCR22 modules. MLPA was performed using the SALSA P356 kit on 
eight subjects with insufficient DNA amount for qPCR, and the deletion in these 
 
 
 
occurred distal to PRODH, however, the precise breakpoint interval could not be 
defined using this method (Supplementary Material, Fig. S4). Haplotype and FISH 
analyses to examine 22q11.2 alleles Microsatellite marker based genotyping has 
been previously used to determine the presence and extent of the 22q11.2 deletion 
(12,27) or parent of origin of the deletion (31). Fortunately, one microsatellite marker 
in the 22q11.2 region, termed D22S1638, maps within the breakpoint interval (Fig. 
1A; Supplementary Material, Table S2). The sequence of the D22S1638 PCR 
product is not present elsewhere in the genome, as determined by BLAST (Basic 
Local Alignment Search Tool) and BLAT (BLAST-like Alignment Tool; in the UCSC 
Genome Browser) analyses. We performed haplotype analysis using microsatellite 
genetic markers spanning the 22q11.2 region on DNA samples from 14 probands 
and their parents (Supplementary Material, Fig. S5). A representative example of this 
analysis for the KD23 trio is illustrated in Figure 1C. The parent of origin of a 
particular allele can be identified based upon the presence of particular sized alleles. 
Failure to inherit either allele from one parent indicates that the deletion occurred in 
that particular parent as illustrated in Figure 1A (right). For D22S1638, KD23 is 
informative for inheriting one allele from either parent (Fig. 1C and D). When 
included with results from qPCR assays, in eight of 14 families, haplotype analysis 
confirmed that a de novo LCR22Aþ-B or LCR22Aþ-D deletion had occurred 
(Supplementary Material, Table S4). We next performed metaphase and interphase 
FISH mapping analyses on Epstein-barr virus transformed cell lines available for 
BM1428 and BM355, which are normal, BM293, BM465 and BM1045.001, which 
had the 3 Mb LCR22A-D deletion, and BM1332.001 as well as BM1024.001, which 
are two probands with a nested LCR22Aþ-D deletion. FISH mapping was performed 
using large insert fosmid genomic clones. We used two sets of control fosmids to 
detect the pericentromeric region on the p-arm (green fluorescence color) and the 
TBX1 region, mapping between LCR22A and LCR22B (aqua color; Supplementary 
Material, Fig. S1). One clone (red fluorescence; Supplementary Material, Fig. S1), 
mapped to the breakpoint interval between LCR22A-Aþ(Fig. 1A-red star; 
Supplementary Material, Fig. S1). We observed a green-red-aqua pattern on the 
normal allele of chromosome 22, a green-only pattern in the chromosome with the 
LCR22A-D deletion and a green-red pattern on the chromosome with the LCR22Aþ-
D deletion (Fig. 2A; Supplementary Material, Fig. S1) as illustrated in Figure 2B. The 
counts of hybridization signals in the metaphase spreads and interphase nuclei are 
shown in Supplementary Material, Table S5. FISH mapping visually confirmed the 
occurrence of different types of 22q11.2 deletions found by qPCR assays and 
haplotype analysis using microsatellite markers. 
 
Occasionally, a smaller sized, red signal was observed mapping distal (telomeric) to 
the TBX1 probe (aqua) on the nondeletedchromosome, giving a green-red-aqua-red 
pattern on interphase chromosomes (Fig. 2; Supplementary Material, 
 
 
 
 
 
  
 
  
 
  
Parental samples with a 0.2 Mb duplication of LCR22A-aþ 
 
We investigated the genome structure in available parents of subjects with the 
nested LCR22Aþ-B or LCR22Aþ-D deletions. Surprisingly, among the 14 trios, 12 
probands with the nested deletion had one parent that carried a 0.2 Mb duplication, 
based upon qPCR and microsatellite marker analyses, where the proximal deletion 
endpoint was in LCR22A and the distal was within LCR22Aþ(Fig. 1A; Supplementary 
Material, Figs S1 and S2). We refer to this as the LCR22A-Aþduplication copy 
number variation (CNV; Fig. 1A, top right). We examined the haplotypes from 
microsatellite marker analysis in all families in which one parent carried the LCR22A 
Aþ duplication. For six of the eight families, the de novo deletion occurred in the 
parent that carried the LCR22A-Aþduplication (Supplementary Material, Fig. S4; 
Table S4). We do not have grandparental DNA samples, and thus, we cannot 
unambiguously assign haplotypes of D22S1638 in the parent with the duplication 
CNV. In those six cases, the most parsimonious conclusion is that the deletion 
occurred on the allele other than the one harboring the duplication (Fig. 1C; 
Supplementary Material, Fig. S4; Table S4). For two cases, the nested deletion 
occurred in the meiosis of one of the normal parents, indicating that the presence of 
the LCR22AAþduplication CNV is not required to cause the nested deletion. Based 
upon the presence of a duplication of LCR22A-Aþin one parent, an alternative 
possibility for the remaining six families with a presumed nested deletion, was that 
the proband inherited the LCR22A-Aþduplication on one allele and had a de novo 
typical 3 Mb deletion on the other allele. Indeed, we found by qPCR assays and 
haplotype analysis using microsatellite markers, that the probands in these six 
families inherited one allele with the LCR22A-Aþduplication and had a de novo 3 Mb 
deletion on the other allele derived from the other parent (Supplementary Material, 
Fig. S4; Table S4). Subject, BM293, had a presumed LCR22Aþ-D deletion based 
upon qPCR assays (Supplementary Material, Fig. S3). Only one parent was 
available for haplotype analysis using microsatellite markers, which was 
uninformative (Supplementary Material, Fig. S2). However, we performed FISH 
mapping and found that BM293 had a 3 Mb LCR22A-D deletion on one allele 
because there was only the centromeric signal present on one allele of 22q11.2 
(Supplementary Material, Fig. S1). However, subject BM293 had two copies of the 
LCR22A-Aþallele based upon qPCR (Supplementary Material, Fig. S3) and had two 
different alleles for marker, D22S1638 (Supplementary Material, Fig. S5). Upon 
examination of the other allele by FISH mapping, it appeared that the red signal 
(DGCR5; LCR22A-Aþregion) was larger in diameter, which would be consistent with 
the presence of a duplication of the LCR22AAþregion on one allele (Supplementary 
Material, Fig. S1). Overall, there are three types of deletions based upon the data we 
presented, and these are illustrated in the cartoon in Figure 3. Each allele is color-
coded to visualize the haplotypes in the proband and where they are derived. For the 
type A deletion, the proband had a typical de novo 3 Mb deletion and inherited a 
LCR22A-Aþduplication on the other allele, from the other parent. For the type B 
deletion, the proband had a de novo LCR22Aþ-B or LCR22Aþ-D deletion that 
occurred in the parent that had a LCR22A-Aþduplication. The most parsimonious 
explanation is that the deletion occurred on the other allele from the allele with the 
LCR22A-Aþduplication. For the type C deletion, the proband had a de novo 
LCR22Aþ-B or LCR22Aþ-D deletion from parents that did not have a 
LCR22AAþduplication, but instead had two normal copies of chromosome 
22. In all these examples, all subjects had two copies of three genes, coding genes 
DGCR6 and PRODH as well as the noncoding gene, DGCR5 (Fig. 1A). 
Population frequency of the LCR22A-Aþdeletion and duplication We next were 
interested in determining the relative frequency of the seemingly benign LCR22A-
Aþduplication CNV in the general population. Representative examples of log2 ratio 
plots from Affymetrix 6.0 arrays of two normal individuals with a deletion or 
duplication of the LCR22A-AþCNV are shown in Supplementary Material, Figure S7. 
A recurrent LCR22AAþdeletion of this interval has been previously described, in 
rare cases of hyperprolinemia when accompanied with an inactivating point mutation 
of PRODH on the other allele (33,34). To determine the frequency of the LCR22A-
Aþdeletion or duplication CNV, we examined existing published and unpublished 
microarray data as summarized in Table 2 and shown separated by cohort in 
Supplementary Material, Table S6. The LCR22AAþdeletion CNV occurred in 0.3% of 
15 579 normal individuals from the general population and 0.3% of 20 987 
individuals with developmental delay, autism or other developmental disorders. 
Since the frequencies for the occurrence of the deletion were the same in normal 
individuals versus individuals with phenotypic abnormalities, it is possible that the  
 
 
deletion is benign. The LCR22A-Aþduplication CNV on the other hand occurred in 
1.3% of normal or affected individuals (Table 2; Supplementary Material, Table S6). 
As for the LCR22A-Aþdeletion, the common duplication CNV seems benign. The 
duplication occurs 4.3-fold more frequently than the LCR22A-Aþdeletion CNV. 
Based upon this, it is possible that the deletion CNV has some biological function 
and some effect on phenotype, but it was not identified using this population data. 
 
 
 
Genomic architecture of LCR22Aþ 
Next, we wanted to investigate the architectural features of LCR22Aþ(Fig. 4A). There 
is one CpG island within LCR22Aþ, but no obvious active or repressive chromatin 
marks that are apparent in ENCODE tracks from the UCSC Genome Browser (data 
not shown). We examined possible genes that might map within LCR22Aþ. A splice 
variant of the long interspersed noncoding RNA (lincRNA) encoded by DGCR5 (35), 
extends within LCR22Aþas illustrated in Figure 4A. Two other non-coding RNA 
genes, DGCR9 and DGCR10 map just proximal to LCR22Aþ, and appear to be 
alternative splice forms of DGCR5 (Fig. 4A, UCSC Gene and lincRNA tracks in the 
UCSC Genome Browser). Upon examination of GTEx (Genotype-Tissue Expression 
project; https://www.gtexportal.org/home/; data not shown) and lincRNA RNA-seq 
data from adult human tissues (36), DGCR5, DGCR9 and DGCR10 (AC000095) are 
highly specifically expressed in the brain (Fig. 4A). LCR22Aþcontains a non-
functional partial copy of the Car15 gene, which encodes a carbonic anhydrase 
protein in the mouse and rat (37) (Fig. 4A). It does not appear to be complete or 
functional in humans. The PRDM9 protein is essential for homologous recombination 
in humans (38,39). There are 13 potential PRDM9 sites in LCR22Aþ (Supplementary 
Material, Table S7), suggesting that at least some of them might be involved in the 
recombination process that leads to recurrent meiotic rearrangements involving 
LCR22Aþ. LCR22Aþmaps in two other locations on 22q11.2 as determined by BLAT 
analysis using the UCSC Genome Browser hg19 assembly (19,40). One of the two 
copies maps within LCR22B and the second maps within LCR22D (Supplementary 
Material, Fig. S8). We can conclude that this LCR has been quite active in 
recombination processes during primate evolution. 
 
 
 
 
 
Balanced translocation maps to LCR22Aþ 
It is unknown whether there is a hotspot for chromosome rearrangements within 
LCR22Aþ. There could be a clue from other rearrangements involving this LCR. We 
examined the literature for other types of rearrangements in LCR22Aþand found 
previous reports of a family whose breakpoint was cloned and sequenced (41) that 
carried a balanced t(2; 22)(q14; q11.21) translocation in which the proband and 
mother, ADU and VDU, respectively, had features of 22q11.2DS (42). This family 
historically was the subject of much interest in the field because the affected proband 
and mother did not have a deletion but had a balanced translocation, which 
disrupted DGCR5 (35). Of interest, the translocation breakpoint is within the center 
of LCR22Aþas illustrated in Figure 4A. We may consider this region in the future 
when we are able to narrow LCR22Aþ-B or Aþ-D deletion endpoints that it might 
serve as a hotspot for chromosome rearrangements. 
LCR22Aþmaps to an evolutionary breakpoint The largest region of synteny to human 
22q11.2 maps to mouse chromosome 16. There are inversions and some shuffling 
of genes between the two species (39,43,44), and some of the evolutionary 
breakpoints between sets of genes appear to be where the LCR22s map in humans 
as shown in Figure 5 (39,43,44). The mouse genome does not contain LCR22s as 
can be visualized in Figure 5. In the human genome, the order of the adjacent genes 
is: DGCR6, PRODH, DGCR5 and DGCR2 (DGCR5 is not shown in Figure 5, since it 
is a non-coding gene). In the mouse genome, the order of genes on chromosome 16 
is Klhl22 (Kelch like family member 22), Scarf2 (scavenger receptor class F member 
2), Car15 and Dgcr2 (DiGeorge critical region gene 2) (Fig. 4B). In humans, 
the KLHL22 and SCARF2 genes map 1.7 Mb away from LCR22Aþ, distal (telomeric) 
to LCR22B. The DGCR5 non-coding gene does not appear to be present in the 
mouse genome. Thus, LCR22Aþmaps to a region of an evolutionary breakpoint 
between the two species. 
 
Discussion 
In this report, we identified a recurrent chromosome 22q11.2 rearrangement hotspot 
in a small, 12 kb segmental duplication or low copy repeat, referred to as LCR22Aþ. 
Breakpoints within LCR22Aþare associated with rare nested de novo deletions in 
 
 
 
 
 
22q11.2DS patients. Breakpoints in LCR22Aþalso occur within an inherited common 
seemingly benign duplication CNV of 0.2 Mb termed LCR22A-Aþ, harboring two 
coding genes, DGCR6 and PRODH and one non-coding gene, DGCR5. The 
LCR22Aþ-B or LCR22Aþ-D deletions occur twice as often from a parent with the 
LCR22Aþ duplication CNV, implicating increased risk for this type of deletion. Of 
interest, a balanced translocation reported previously in one family, ADU/VDU (41), 
maps within LCR22Aþ. It is possible that the position of the breakpoint might be 
similar to the recurrent one in the subjects with LCR22Aþ-B or LCR22Aþ-D 
deletions. We suggest that LCR22Aþmay be vulnerable tomeiotic chromosomal 
rearrangements. The results underscore the importance of structural genomic 
features in mediating genomic variation and disease (20). The breakpoint is of 
interest evolutionarily because LCR22Aþ maps to an evolutionary breakpoint 
between mouse and human genomes, in which the non-coding DGCR5 gene seems 
to be human specific and the Car15 gene seems to be mouse specific. Thus, this 
region has apparent disease-related importance as well as importance in the 
evolution of complex regions of the human genome.  
 
Understanding mechanisms for 22q11.2 rearrangements 
 
One of the important goals in the field is to identify regions of chromosome breakage 
within LCR22s in individuals with the typical 3 Mb LCR22A-D deletion. This might 
help identify potential recombination hotspots and molecular mechanisms. The 
typical 22q11.2DS deletion occurs largely by de novo NAHR events between the two 
LCR22s. It has not been possible to identify the chromosome breakpoints within 
LCR22A and LCR22D, despite many efforts, due to their complex structure and high 
sequence homology (13,16,31,45). To add to the complexity, a predisposing 
inversion polymorphism was discovered between LCR22B-D or LCR22C-D, in which 
94% of transmitting parents of individuals with de novo 22q11.2 deletions possess 
the inversion (18).  
Since the proximal breakpoint in the 22q11.2DS subjects with nested LCR22Aþ-B or 
LCR22Aþ-D deletions occurred in LCR22Aþ, it would be of interest to determine 
whether the inversion polymorphism occurs in parents or whether the nested 
deletion occurs as a result of a different mechanism. The data we have support a 
different mechanism. There are two additional copies of LCR22Aþ, one in LCR22B 
and the other in LCR22D, with 97.7% sequence identity. The inversion promotes a 
specific direct orientation of modules or subunits within these duplications, for other 
NAHR mediated disorders (46–50). The orientation of LCR22Aþ in LCR22B is the 
same as for the one between PRODH-DGCR2, but is in the opposite orientation in 
LCR22D. If the inversion existed in the parent in which the deletion occurs, the 
presence of an inversion between LCR22C-D or B-D would cause LCR22Aþin 
LCR22B or –D to be in the opposite orientation needed for a NAHR event between 
LCR22Aþ-D. Thus, it is difficult to envision a simple NAHR mechanism between 
copies of LCR22Aþthat is responsible for these atypical recurrent nested deletions. 
We were not able to narrow the breakpoints within LCR22Aþin our cohort. This is 
because we found that the copies of LCR22Aþin LCR22B and LCR22D are 
embedded within other LCR22 sequences. This situation makes it very challenging 
to clone and sequence the 12 kb, LCR22Aþfragment at this time since flanking 
primers are needed on both sides. Further, the genome architecture of the LCR22s 
are still not completely defined. Currently, the copy of LCR22Aþwithin LCR22B in the 
hg19 genome assembly from 2009, maps within LCR22A in the hg38 genome 
assembly from 2013 (chr22: 18627728–18639943). In addition, there are several 
non-sequenced gaps, both within LCR22A in hg38 that are not present in hg19, 
while there is a similar sized gap in LCR22B in both assemblies. When taken 
together, it appears that the genome architecture of the LCR22s is still not defined. 
Another possibility is that there is extensive variation of the structure or sequence of 
LCR22s within individuals that can add to their complexity. One clue comes from the 
cloned and sequenced breakpoint of the balanced translocation patients ADU/VDU 
that maps in the center of LCR22Aþ. However, it would only be possible to draw a 
conclusion once the chromosome breakpoints for individuals with nested 
LCR22Aþ-B or LCR22Aþ-D deletions are cloned and sequenced. 
We previously performed whole genome sequencing of DNA from two trio families 
with the LCR22A-D deletion and was able to narrow, but not able to precisely define 
the position of the chromosome breakpoints (31). Currently, Bionano optical 
nextgeneration structural mapping is being used to define the architecture of the 
genome (18). It is likely that this sequencing method, or others that will likely 
emerge, will be required to determine the genome architecture of the region, 
chromosome breakpoints and the precise mechanisms of chromosome 
rearrangements within the 22q11.2 region. Homologous recombination in humans 
requires function of the PRDM9 gene (38,39). We scanned the DNA sequence in this 
region and found the hotspot motif, CCNCCNTNNCCNC (38,39), present in three 
locations and the hotspot motif, CCTCCCT (38,39) present in ten locations in 
LCR22Aþ. The hotspot motifs can potentially mediate mammalian homologous 
recombination (Supplementary Material, Table S7). However, it is not known whether 
these sites are active in this process. We did not find a PRDM9 site at the position of 
the ADU/VDU breakpoint. Nonetheless, it is possible that the relevant breakpoint 
events may occur due to other mechanisms. Of interest, six of the eight subjects with 
LCR22Aþto LCR22B or LCR22D deletions occurred as a de novo meiotic event from 
a parent with a 0.2 Mb LCR22A-LCR22Aþduplication. The qPCR, microsatellite and 
FISH results suggest that the nested 22q11.2 deletion may occur on the opposite 
allele that carried the 0.2 Mb LCR22A-LCR22Aþduplication CNV, although the 
mechanism is unknown. 
The Williams-Beuren syndrome (WBS) is a rare neurodevelopmental disorder 
occurring in 1/7500 individuals, caused by NAHR events between complex, region 
specific LCRs on 7q11.23. A chromosome inversion polymorphism flanked by LCRs 
occurs in 25% of transmitting parents compared with 5% in the population (49,50). 
There are further structural polymorphisms within the LCRs on chromosome 7q11.23 
(51). It was found in a cohort of 180 WBS subjects that 4.4% of the parents have a 
deletion of one of the LCR blocks, containing pseudogenes, versus 1% that do not, 
resulting in a significant increase in risk for the deletion[odds ratio of 4.6; P¼0.002; 
or risk of 1/1500 individuals (52)]. The positions of the chromosome breakpoints 
could be mapped to a particular region using paralogous sequence variants but they 
did not map to a particular site within the LCR block (52). It was suggested that this 
LCR block might contain higher sequence identity therefore increasing the frequency 
of NAHR events (52). Structural polymorphisms in the duplications might predispose 
individuals to further meiotic NAHR events (53,54). This would be consistent with the 
possibility that a duplication of LCR22Aþmight predispose individuals to further 
NAHR events or other mechanisms. This will have to be investigated in the future by 
large population studies. 
 
Differences in phenotypes between LCR22A-D versus LCR22Aþ-D deletions 
 
It is possible that there are phenotypic consequences as to whether or not there is 
one versus two copies of PRODH, DGCR6 or DGCR5 genes. This is for all subjects 
with a presumed LCR22Aþ-D deletion. The heterozygous LCR22A-LCR22Aþdeletion 
occurring in 0.3% in the general population is present in approximately 20% of 
individuals with hyperprolinemia when accompanied by a sequence mutation in the 
other allele of PRODH (33,34,55). This is one example how there could be 
phenotypic consequences whether PRODH is deleted on one allele or both alleles. 
Elevated levels of proline in the blood plasma are sometimes associated with clinical 
manifestations including seizures and neurological defects (55–58). This is another 
example of a possible phenotypic consequence, but here it would be in individuals 
that carry the LCR22A-LCR22Aþ duplication CNV. The function of DGCR6 is not 
very well known as compared with PRODH. DGCR6maps just distal to LCR22A. 
However, there is a paralog, termed DGCR6L, which is 97% identical in sequence 
and it maps just proximal to LCR22B (32). The DGCR6/DGCR6L genes are widely 
expressed in most tissues (32). In chicken, Dgcr6 may have a function in embryonic 
development, based upon antisense RNA studies (59), but there are no reports in 
which these genes have been inactivated. There is very little known about the 
function of the long intergenic noncoding RNA gene, DGCR5. This gene appears to 
be absent in nonhuman primate species. 
Approximately, 25% of 22q11.2DS patients develop schizophrenia in adulthood 
(60,61). Although there are many genes hemizygously deleted on 22q11.2, PRODH 
has been of interest in its association with schizophrenia in patients with 22q11.2DS 
(57,62). Glutamine metabolism downstream of hyperprolinemia in affected subjects 
may be disrupted in 22q11.2DS (63). Studies using mouse models to understand the 
function of PRODH have shown that hyperprolinemia might affect glutamatergic 
neurotransmission (64). More recent work in mouse models has shown that loss of 
PRODH may affect GABAergic transmission leading to synaptic dysfunction and 
possibly to behavioral disorders (65). In genetic studies of schizophrenia in the 
general population, there has been a reported association between variants  in 
PRODH, a role in hyperprolinemia and the occurrence of schizophrenia (55,66 70). 
This association remains controversial since other studies do not support a 
connection between PRODH and schizophrenia in the general, non-22q11.2DS 
population (52,66). In the future, it would be of interest to determine whether 
22q11.2DS individuals with both two copies of PRODH have reduced risk to 
schizophrenia. Data for psychiatric phenotypes for this cohort are still being 
collected. Such an evaluation would need to be accompanied by measurement of 
proline levels to confirm that they are normal. 
 
Conclusions 
Using high-resolution Affymetrix 6.0 microarray analysis in a large cohort of 1680 
unrelated 22q11.2DS subjects, we identified LCR22Aþ serving as a hotspot region 
for 22q11.2meiotic and evolutionary rearrangements. The interval where the nested 
proximal breakpoint occurs in individuals with a LCR22Aþ-B or Aþ-D deletion is in 
the same interval as for the distal deletion breakpoint for a common LCR22A-
Aþduplication CNV that contains DGCR6-PRODH-DGCR5 genes. Further a 
balanced translocation in a family with some clinical signs of 22q11.2DS maps to 
specific sequences within LCR22Aþ. It is possible that these sequences might be 
important for chromosome rearrangements. Overall, identification of chromosome 
rearrangement breakpoints inLCR22Aþunderscores the complexity of the genomic 
architecture of the 22q11.2 region. It also highlights the importance of examining the 
genome architecture of parental chromosomes because this might confer risk to 
such rearrangements. 
 
Materials and Methods 
Human subjects 
A total of>1800 genomic DNA samples from unrelated, de identified probands 
with22q11.2DS were ascertained retrospectively from>25 international clinical and 
research sites as part of the International 22q11.2 Consortium and the International 
22q11.2 Brain and Behavior Consortium (Supplementary Material, Table S1), with 
their informed consent (Internal Review Board at Albert Einstein College of Medicine, 
1999–201). All study subjects were unrelated and diagnosed with 22q11.2DS by 
clinical evaluation and by the presence of a 22q11.2 deletion using FISH mapping, 
clinical microarray analysis or Multiplex Ligation-dependent Probe Amplification 
(MLPA) assays (SALSA MLPA kit P250 DiGeorge; MRC Holland, The Netherlands). 
 
Affymetrix SNP 6.0 array processing 
The DNA samples were processed on Affymetrix GeneChip Genome Wide SNP 6.0 
arrays in the Genomics Core of Albert Einstein College of Medicine with the following 
exceptions. A subset had unprocessed Affymetrix 6.0 array data that were                                                  
already available [37 samples from the Advanced Genomics (AGEN) laboratory core 
at the Children’s Research Institute CRI/ MCW, Milwaukee, WI, (21) and 225 Chilean 
samples from the Center for Human Genetics, Clinica Alemana- University 
Desarrollo, Santiago, Chile].  
Quality control (QC) measures were performed on the raw data obtained from 
Affymetrix 6.0 arrays on all samples to ensure good data quality, as specified by the 
microarray manufacturer as previously described (22). The genotype calling methods 
and further QC measures has been previously described (22). In total, 1680 arrays 
from unrelated subjects that passed QC measures were used in this study.  
 
 
Affymetrix SNP 6.0 array 22q11.2 CNV analysis 
Raw intensity data (Affymetrix SNPs 6.0 array CEL file) from each genotyping site 
(Genomics Core; Albert Einstein College of Medicine, CRI/MCW, Milwaukee, WI, 
and Santiago, Chile) were independently processed and analysed to account for 
potential batch effects. Probe intensities were extracted from CEL files and analysed 
using the Copy Number Analysis Module (CNAM) that is part of the Golden Helix 
Powerseat Package (http://www.goldenhe lix.com/index.html). In brief, the 
normalized intensity data for each probe (both SNP-single nucleotide polymorphism 
probes and CNV-copy number variant probes) fromboth 22q11.2DS samples, and 
the reference control (‘baseline’) CEL files were used to calculate the log2 intensity 
ratio (LR). A total of 90 different reference healthy control samples were processed 
at the same time as two batches of 22q11.2DS samples at Albert Einstein College of 
Medicine. For the 22q11.2DS samples processed at CRI/MCW, Milwaukee, WI, the 
270 Affymetrix HapMap pre-computed intensity data were used to calculate the log2 
ratio. Similar to samples at Albert Einstein College of Medicine, 30 and 47 reference 
control samples, respectively, were used for the two batches of GR samples from 
Santiago, Chile. All the data were analyzed as separate batches. Although the raw 
signal intensities were normalized prior to the log ratio (LR) calculation to identify 
deletion size, some variation usually remained. To further remove batch effects and 
other technical artifacts, principal component analysis (PCA) was used to detect and 
correct the data from batch effects. A univariate analysis was implemented using the 
Copy Number Analysis Method (CNAM) of Golden Helix to determine the optimal 
segmentation of the PCA-corrected LR for each measured subject. Two 
measurements including Derivative log ratio spread (DLRS) (23) and Waviness 
factor (24), which derived from Log2 ratio were used as a quality control. The 
samples with greater than 1.5*Interquartile range (IQR) above the upper quartile, or 
less than 1.5*IQR below the lower quartile were removed for further univariate 
analysis to determine the optimal segmentation. Removed samples were analyzed 
by visualizing the log2 ratio plotmanually.  
 
MLPA analysis 
A total of 539 samples received since 2015, among the 1680, were tested by MLPA 
using the SALSA P250-B2 kit (MRC Holland, Amsterdam, The Netherlands) 
containing 15 probes from the LCR22A through –D region. This kit does not contain 
a probe in the LCR22A-Aþregion. The SALSA P356 kit for the q arm of chromosome 
22 was used on the subset of DNA samples from Santiago, Chile. In this kit, there 
are two probes for PRODH, mapping to the LCR22A-Aþregion and five other probes 
in the LCR22A-D region. A total of 100–250 ng of DNA in a final volume of 5 ml was 
heated at 98_C and mixed with 1.5 ml probe mix and 1.5 ml SALSA hybridization 
buffer. Probe hybridization, ligation and amplification reactions were carried out 
according to the protocols supplied by MRC Holland in a standard thermal cycler 
(Tpersonal, BiometraVR, Go¨ ttingen, Germany). The amplification products were 
analyzed by capillary electrophoresis in an ABI 3730XL genetic analyzer, using the 
GeneMapper software v3.5 (Applied Biosystems), following the recommended 
protocol supplied with the MLPA kit. Raw data were exported and normalization was 
performed using internal control and reference probes as previously described 
(25,26). This set values for diploid gene dosage to 1, with deletion and duplication 
thresholds established at below 0.75 and above 1.25, respectively. Quantitative PCR 
analysis Confirmation of deletion endpoints was performed by quantitative PCR 
(qPCR) using the SYBR Green-based detection method. The qPCR was carried out 
on an ABI StepOnePlusTM System. Primer 3.0 software 
(http://simgene.com/Primer3) was used to design primers to amplify the regions of 
interest listed in Supplementary Material, Table S2. Each qPCR assay included 
amplification of three endogenous control samples with known copy number (control 
reference assay: telomerase reverse transcriptase, TERT; Ribonuclease P RNA 
component H1, RPPH1; RnaseP). One DNA sample with normal copy number 
(CEPH HapMap sample GM12878) was used as a control in each experiment. A 
total of 10 lL reactions were performed using 10 ng of DNA following the 
manufacturer’s recommended protocol. 
Results were analyzed using StepOnePlusTM Software based on the DDCT method. 
Microsatellite marker assays and haplotype analysis Microsatellite marker 
polymorphism data were collected using a panel of eight simple tandem repeat 
markers (D22S427, D22S1638, D22S941, D22S944, D22S264, D22S311, 
D22S1709A, D22S308) (27,28). The forward primer for each marker was labeled 
with FAM for D22S427, NED for D22S1638, FAM for D22S941, TET for D22S944, 
VIC for D22S264, HEX for D22S1709A, PET for D22S311, PET for D22S308 
(Supplementary Material, Table S2). We generated a new microsatellite marker that 
we named BCRP2 and it was labeled with NED (Supplementary Material, Table S2). 
PCR was performed using standard conditions optimized for each marker. The 
amplified products were diluted with water, to obtain a fluorescence signal strength 
between 1000 and 18 000 relative fluorescence units and the samples were run on 
an ABI PRISM 3730 sequencer. The .fsa files from the ABI 3730 sequencer were 
analyzed with GeneMarkerVR V1.75 software (SoftGenetics, State College; PA 
http://www.soft genetics.com/GeneMarker.php) to size and call alleles in base 
pairs (bp). All allele calls were manually reviewed. FISH mapping Fosmid clones 
were identified using the UCSC Genome Browser for the human genome, assembly 
GRCh37/hg19. The bacterial colonies containing the fosmid clones were purchased 
from BAC-PAC Resources (https://bacpacresources.org/WIBR-2: Human Fosmid 
Library). The sequence of the purchased fosmid clones was confirmed using PCR 
with primers designed from unique sequence within each clone (Supplementary 
Material, Table S2). Two fosmids were chosen to mark unique sequences just 
telomeric to the pericentromeric region on 22q11.1 containing the CECR1 gene (DY-
495-dUTP; Spectrum green; Fluorescein isothiocyanate-FITC), one in the LCR22A-
Aþregion, containing DGCR5 (DiGeorge syndrome Critical Region 5) (DY-590-dUTP; 
Spectrum orange; S.O.) and two in the TBX1-GNB1L region (DY- 415-dUTP; 
spectrum aqua). Dyes were purchased from Dyomics (Jena, GE). Detailed 
information about the map position of the fosmids are shown in Supplementary 
Material, Figure S1. FISH mapping was performed on actively growing Epstein Barr 
virus (EBV) transformed lymphoblastoid cell lines from blood samples using the 
probes. Briefly, the slides for FISH mapping were denatured with 50% 
Formamide/2xSSC at 72_C for 1.5 min and then dehydrated with serial ethanol 
washing steps (ice cold 70, 90 and 100% for 3 min each). Probes were denatured in 
the hybridization solution (50% dextran sulfate/2xSSC) at 80_C for 7 min, applied to 
the slides and incubated overnight at 37_C in a humidified chamber. The slides were 
then washed three times for 5 min with 50% formamide/2X SSC, 1X SSC and 
4XSSC/ 0.1%Tween. Slides were dehydrated with serial ethanol washing steps (see 
above) and mounted with ProLong Gold antifade reagent with DAPI (4, 6-Diamidino-
2-phenylindole; Invitrogen, Carlsbad, CA) for imaging. FISH images were acquired 
with a manual inverted fluorescence microscope (Axiovert 200, Zeiss) 
with a fine focusing oil immersion lens (x40, NA 1.3 oil and “60, NA 1.35 oil). Multiple 
focal planes were acquired for each channel to ensure that signals on different focal 
planes were included. The resulting fluorescence emissions were collected using 
350-to-470 nm (for DAPI), 436-to-480 nm (for DY-415- dUTP), 470-to-540 nm (for 
DY-495-dUTP and Alexa Fluor 488) and 546-to-600 nm (for DY-590-dUTP an Alexa 
Fluor 555) filters. The microscope was equipped with a Camera Hall 100 and we 
used Applied Spectral Imaging software. 
 
Supplementary Material 
Supplementary Material is available at HMG online. 
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